While world’s governments are making emergency provisions to prevent nasty variants of Covid-19 from decimating India (see here), Immunome, Inc. (IMNM) just asserted itself as a major defense against the threat of mutational drift.
This morning, the company announced the components of its novel B-cell antibody cocktail.
Here’s what immediately stands out and matters…
1. Serious Defense Against Variants
Remember, every vaccine in use today – and the most promising one being developed by Novavax, Inc. (NVAX) – only target a single spike protein. That means they’re increasingly less effective in treating mutations of the virus.
Not Immunome, though.